Rafferty Asset Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.46M | Sell |
71,558
-36,780
| -34% | -$748K | ﹤0.01% | 686 |
|
|
2025
Q1 | $1.97M | Sell |
108,338
-44,116
| -29% | -$801K | 0.01% | 584 |
|
|
2024
Q4 | $3.85M | Buy |
152,454
+61,464
| +68% | +$1.55M | 0.01% | 464 |
|
|
2024
Q3 | $3.09M | Sell |
90,990
-28,504
| -24% | -$969K | 0.01% | 531 |
|
|
2024
Q2 | $4.42M | Sell |
119,494
-71,921
| -38% | -$2.66M | 0.02% | 446 |
|
|
2024
Q1 | $8.03M | Buy |
191,415
+43,406
| +29% | +$1.82M | 0.03% | 345 |
|
|
2023
Q4 | $5.87M | Sell |
148,009
-16,781
| -10% | -$666K | 0.02% | 407 |
|
|
2023
Q3 | $4.54M | Sell |
164,790
-40,718
| -20% | -$1.12M | 0.03% | 402 |
|
|
2023
Q2 | $6.97M | Buy |
205,508
+59,772
| +41% | +$2.03M | 0.04% | 345 |
|
|
2023
Q1 | $5.24M | Buy |
145,736
+2,405
| +2% | +$86.5K | 0.04% | 374 |
|
|
2022
Q4 | $6.39M | Sell |
143,331
-64,362
| -31% | -$2.87M | 0.05% | 322 |
|
|
2022
Q3 | $5.84M | Buy |
207,693
+83,887
| +68% | +$2.36M | 0.06% | 300 |
|
|
2022
Q2 | $3.34M | Sell |
123,806
-32,446
| -21% | -$875K | 0.03% | 369 |
|
|
2022
Q1 | $5.32M | Buy |
156,252
+12,137
| +8% | +$413K | 0.03% | 377 |
|
|
2021
Q4 | $5.57M | Buy |
144,115
+86,971
| +152% | +$3.36M | 0.03% | 346 |
|
|
2021
Q3 | $3.09M | Sell |
57,144
-21,357
| -27% | -$1.15M | 0.02% | 462 |
|
|
2021
Q2 | $2.63M | Sell |
78,501
-42,558
| -35% | -$1.42M | 0.02% | 566 |
|
|
2021
Q1 | $2.49M | Buy |
121,059
+95,268
| +369% | +$1.96M | 0.02% | 567 |
|
|
2020
Q4 | $452K | Buy |
+25,791
| New | +$452K | ﹤0.01% | 706 |
|